Trial Profile
Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Administered to at Risk Subjects From 1 to Less Than 18 Years
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Jan 2024
Price :
$35
*
At a glance
- Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
- Indications Meningitis
- Focus Pharmacodynamics; Registrational
- Acronyms MENACWY-TT-084
- Sponsors GlaxoSmithKline; GSK
- 22 Mar 2018 Results published in the Vaccine
- 05 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 23 Nov 2014 Planned End Date changed from 1 Apr 2015 to 1 May 2015 as reported by ClinicalTrials.gov record.